Maxim Group Reiterates $5 Price Target on Mast Therapeutics (MSTX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
Mast Therapeutics (MSTX) Offers Business Update; Phase 3 EPIC Enrollment Surpasses 90% Mark
January 7, 2016 8:06 AM ESTMast Therapeutics, Inc. (NYSE: MSTX) provided a business update.
The Company reported that patient enrollment in the pivotal Phase 3 "EPIC" study of its lead product candidate, vepoloxamer (MST-188), in sickle cell disease recently surpassed the 90% mark. The Company expects to complete patient enrollment in February. Consistent with prior guidance, the Company expects to report top-line results in the second quarter of... More